Evidence map›Paper›PMID 20462946›Full record

ArticleThe Journal of antimicrobial chemotherapy2010

Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

Elizabeth C Reuman, Soo-Yon Rhee, Susan P Holmes, Robert W Shafer

Open access · greenAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Drug resistance patterns in HIV patients with virologic failure in Iran.Archives of clinical infectious diseases · 2019
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Elizabeth C ReumanDivision of Infectious Diseases, Department of Medicine, Stanford University, 300 Pasteur Drive, Grant S-146, Stanford, CA 94305, USA. ereuman@stanford.edu
Soo-Yon Rhee
Susan P Holmes
Robert W Shafer
Stanford University · US

Funding

PUBLIC HIV DRUG RESISTANCE DATABASER01AI068581 · NIAID · STANFORD UNIVERSITY · PI SHAFER, ROBERT WILLIAM · 2006 to 2017
$6.2M
IDENTIFICATION OF MULTIDRUG RESISTANT HIV1 ISOLATESR01AI046148 · NIAID · STANFORD UNIVERSITY · PI SHAFER, ROBERT WILLIAM · 1999 to 2008
$2.4M
Heterogeneous in situ data: Kernals, Distances and TreesR01GM086884 · NIGMS · STANFORD UNIVERSITY · PI HOLMES, SUSAN P · 2008 to 2011
$895k
PUBLIC HIV DRUG RESISTANCE DATABASER56AI068581 · NIAID · STANFORD UNIVERSITY · PI SHAFER, ROBERT WILLIAM · 2013 to 2013
$729k
NIAID NIH HHS AI068581NIAID NIH HHS AI46148NIGMS NIH HHS R01 GM086884NIGMS NIH HHS R01GM086884
6 · The paper itself

Abstract

objectivesWe characterized pairwise and higher order patterns of non-nucleoside reverse transcriptase inhibitor (NNRTI)-selected mutations because multiple mutations are usually required for clinically significant resistance to second-generation NNRTIs. PATIENTS AND

methodsWe analysed viruses from 13 039 individuals with sequences containing at least one of 52 published NNRTI-selected mutations, including 1133 viruses from individuals who received efavirenz but no other NNRTI and 1510 viruses from individuals who received nevirapine but no other NNRTI. Of the 17 reported etravirine resistance-associated mutations (RAMs), Y181C/I/V, L100I, K101P and M230L were considered major based on published in vitro susceptibility data.

resultsEfavirenz preferentially selected for 16 mutations, including L100I (14% versus 0.1%, P < 0.001), K101P (3.3% versus 0.4%, P < 0.001) and M230L (2.8% versus 1.3%, P = 0.004), whereas nevirapine preferentially selected for 12 mutations, including Y181C/I/V (48% versus 6.9%, P < 0.001). Twenty-nine pairs of NNRTI-selected mutations covaried significantly, including Y181C with seven other mutations (A98G, K101E/H, V108I, G190A/S and H221Y), L100I with K103N, and K101P with K103S. Two pairs (Y181C + V179F and Y181C + G190S) were predicted to confer >10-fold decreased etravirine susceptibility. Seventeen percent of sequences had three or more NNRTI-selected mutations, mostly in clusters of covarying mutations. Many clusters had Y181C plus a non-major etravirine RAM; few had more than one major etravirine RAM.

conclusionsAlthough major etravirine RAMs rarely occur in combination, 2 of 29 pairs of covarying mutations were associated with >10-fold decreased etravirine susceptibility. Viruses with three or more NNRTI-selected mutations often contained Y181C in combination with one or more minor etravirine RAMs; however, phenotypic and clinical correlates for most of these higher order combinations have not been published.

Indexed as

Drug Resistance, Multiple, ViralMutation, MissenseAlkynesAmino Acid SubstitutionAnti-HIV AgentsBenzoxazinesCyclopropanesDNA Mutational AnalysisFemaleHIV-1HIV InfectionsHIV Reverse TranscriptaseHumansMaleNevirapineNitrilesAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesefavirenzetravirineHIV Reverse TranscriptaseNevirapineNitrilesPyridazinesPyrimidinesreverse transcriptase, Human immunodeficiency virus 1Reverse Transcriptase Inhibitors

Identifiers

PMID20462946
PMCPMC2882873
OpenAlexW2160877552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.